Quantcast
Channel: Tracxn Blog
Viewing all articles
Browse latest Browse all 2659

Tracxn – Analyst Notes # 1263 – Biopharma (by Disease)

$
0
0

Soonicorn Club

  • Soonicorn

    Indiabulls Pharmaceuticals (2016, Mumbai, $24M) – Company selling over 300+ generic products and medical devices for both chronic and acute therapies
    Market: Biopharma (by Disease) > Traditional Pharma > Generics

  • Minicorn

    Relay Therapeutics (2016, Cambridge, $120M) – Drug discovery platform centered on protein motion
    Market: Biopharma (by Disease) > Oncology

  • Minicorn

    Allakos (2012, San Mateo, $142M) – Develop therapeutic antibodies for the treatment of allergic, inflammatory, and proliferative diseases
    Market: Biopharma (by Disease) > Immune Disease

Analyst Picks

  • Jnana Therapeutics (2017, Boston, $50M) – Company developing a drug discovery platform for targeting the solute carrier (SLC) family of transporters
    Market: Biopharma (by Disease) > Suite
  • Istesso (2017, London) – Immunometabolism based drugs for autoimmune diseases
    Market: Biopharma (by Disease) > Immune Disease
  • Inozyme Pharma (2016, Cambridge, $49M) – Company developing novel treatments for rare calcification disorders
    Market: Biopharma (by Disease) > Metabolic Disease
  • Vaccitech (2016, Oxford, $14.4M) – Vaccines and immunotherapies for infectious diseases and cancer
    Market: Biopharma (by Disease) > Suite
  • Refuge Biotech (2016, Menlo Park) – Company using CRISPR activation and CRISPR interference to develop novel cancer treatments
    Market: Biopharma (by Disease) > Oncology > Pan-Cancer

Funding Rounds

Post IPO, $125M
ERYtech Pharma (2004, Lyon, $15.8M) – cancer therapies using proprietary technology based on encapsulation of therapeutic molecules into red blood cells.

Series B, $114M
Semma Therapeutics (2014, Boston, $158M) – Bio-Artificial Pancreas for Type 1 Diabetes treatment

Investors: Eight Roads Ventures, Cowen, MPM Capital, FPrime Capital Partners, ARCH Venture Partners, Medtronic, Novartis, JDRF, Shuanghu capital investment, Sinopharm Capital, WuXi Healthcare Ventures

Post IPO, $110.7M
ALK-Abello (1923, Hoersholm) – Danish, Public Biopharma company developing allergy immunotherapies including injections (emergency) and sublingual tablets.

Series B, $100M
Allakos (2012, San Mateo, $142M) – Develop therapeutic antibodies for the treatment of allergic, inflammatory, and proliferative diseases

Investors: New Enterprise Associates, Redmile Group, Partner Fund Management, Roche, RiverVest Venture Partners, Alta Partners, Rock Springs Capital, LifeSci Venture, Samsara, undefined

Conventional Debt, $100M
Recro Pharma (2007, Malvern, $16M) – Non-opioid therapeutics for the treatment of pain and CDMO services for oral dosage forms

Investors: Athyrium Capital Management

Series C, $76.5M
Codiak BioSciences (2015, Woburn, $170M) – Developing exosomes (natural vesicles) based drugs and diagnostics for cancer.

Investors: ARCH Venture Partners, Flagship Pioneering, Fidelity Investments, Alaska Permanent Fund, Qatar Investment Authority, SIRONA CAPITAL, EcoR1 Capital, Casdin Capital, Alexandria Venture Investments, Tavistock Group

Post IPO, $76M
Zensun (2000, Shanghai) – Chinese Biopharma company developing Protein and Gene Therapies

Investors: SDIC, Tianfeng Tianrui Investment, Orient Securities, China Venture Capital

Series B, $62M
Pionyr Immuntherapeutics (2015, San Francisco, $72M) – Cancer immunotherapies that target the tumour microenvironment to enhance the body’s antitumour immunity

Investors: Sofinnova Ventures, Orbimed, SV Health Investors, Osage Partners, Mission Bay Capital, New Enterprise Associates

Series C, $59.6M
Hookipa Biotech (2011, Vienna, $103.4M) – Genetic vaccines for the prophylactic and therapeutic treatment of viral diseases

Investors: HBM Partners, Hillhouse Capital Group, SIRONA CAPITAL, Gilead Sciences, Hookipa Biotech, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures, BioMedPartners

Series B, $57M
Medeor Therapeutics (2014, San Mateo, $57M) – Developing personalised cellular therapeutics to improve kidney transplant organ and kidney transplant recipient outcomes.

Investors: RA Capital Management, Sofinnova Ventures, WuXi Healthcare Ventures, Vivo Capital

Post IPO, $50.1M
Advanced Oncotherapy (2013, London) – Particle therapy systems that makes radiation less toxic for patients

Series A, $50M
Jnana Therapeutics (2017, Boston, $50M) – Company developing a drug discovery platform for targeting the solute carrier (SLC) family of transporters

Series A, $49.5M
Obsidian Therapeutics (2015, Cambridge, $49.5M) – Company developing destabilizing domain based technologies to regulate CAR-T and gene-based therapies

Investors: GV, Atlas Venture, Takeda Ventures, Vertex Ventures HC, Amgen Business Development, Alexandria Venture Investments, ShangPharma

Series A, $49M
Inozyme Pharma (2016, Cambridge, $49M) – Company developing novel treatments for rare calcification disorders

Investors: Longitude Capital, New Enterprise Associates, Novo Holdings, Sanofi Ventures

Series B, $40M
Restorbio (2016, Boston, $65M) – Therapeutics for preventing immunosenscence

Investors: Orbimed, Rock Springs Capital, Quan Capital, Fidelity Investments, Nest Bio Ventures

M&A

  • Gilead Sciences and Kite to Acquire Cell Design Labs Business Wire
  • SK Capital Closes Acquisition of Perrigo’s API Business, Changes Name to Wavelength Pharmaceuticals pharmoutsourcing.com
  • Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain PressReleasePoint
  • bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to PatientsBusiness Wire
  • NuVasive To Acquire SafePassage OrthoSpineNews
  • ImmunoPrecise to Acquire ModiQuest Research BV PR Newswire
  • CanniMed to Acquire Up Cannabis Inc to Create a Premier Global Cannabis CompanyBusiness Wire
  • Torrent Pharma completes acquisition of Unichem Laboratories Ltd Indiatimes
  • Wize Announces Closing of Merger 4-Traders
  • Monster Digital, Inc. Provides Update Regarding Anticipated Closing Date for Merger with Innovate Biopharmaceuticals, Inc. NewMediaWire

IPO

  • Denali Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
  • Odonate Therapeutics Seeks $182.5M In IPO TexasTechPulse
  • Arsanis Announces Closing of Initial Public Offering BioSpace
  • Odonate down after $150M IPO BioCentury
  • resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering BioSpace
  • Advicenne launches €30M IPO to be First to treat Rare Disease in Children Labiotech
  • SCPharmaceuticals gets cash injection from IPO Global Corporate Venturing
  • Heat Biologics Announces Proposed Public Offering of Common Stock PressReleasePoint
  • Intellia Therapeutics Closes $150 Million Public Offering of Common Stock Life-Sciences-Germany
  • argenx announces launch of proposed public offering in the United States GlobeNewswire

FDA Approval

  • USFDA gives final approval to Cipla’s anti-asthma product Indiatimes
  • FDA approves first two-drug regimen for certain patients with HIV PR Newswire
  • FDA Approves Foundation Medicine’s FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics Business Wire
  • Zydus gets USFDA nod for seizure, migraine drug Indiatimes
  • FDA Approves Sanofi’s Admelog® (insulin lispro injection) GlobeNewswire
  • Zydus Cadila gets USFDA nod for swelling reducing drug Indiatimes
  • GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis PR Newswire
  • FDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder PR Newswire

New Product Announcement

  • Teva Announces Exclusive Launch of Generic Viagra® Tablets in the United StatesBusiness Wire
  • Biocon Launches Colon Cancer Drug In India, Priced Rs 24,000 Ultra
  • Viagra goes generic: Pfizer to launch own little white pill FOX Business
  • Mylan and Aspen Announce Launch of Generic Busulfex® Injection PR Newswire
  • Amgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients PR Newswire
  • IQVIA Launches Orchestrated Customer Engagement Business Wire
  • Serum Institute to launch 4 vaccines, enter US, Europe markets Indiatimes

New Market Entry

New Geo Entry

  • Biocad Launches The New Manufacturing Site In North Africa Business Wire
  • Aurobindo looks for inorganic growth prospects in East Europe Indiatimes
  • ReNeuron Opens US Office As It Presses On With Clinical Trials LSE Spreads
  • Seqirus readies for $9M expansion project in Holly Springs The Business Journals

Business Partnership

  • AstraZeneca Partners Up With Chinese Fund to Launch New Biopharma CompanyBioSpace

Company Announcement

  • European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon’s Proposed Biosimilars Trastuzumab and Pegfilgrastim PR Newswire
  • U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months Business Wire
  • Glenmark Pharma Announces Top-Line Results From a Phase III Safety Study Evaluating Ryaltris in Patients with Perennial Allergic Rhinitis BioSpace
  • Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
  • Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington’s Disease pipelinereview.com

Earning Release

  • Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update 4-Traders

Research Partnership

  • Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis Business Wire
  • Bayer, PeptiDream partner to identify new active substance candidates through novel peptide-based screening technology Pharma Biz

Layoffs

  • Teva Pharmaceutical set for major layoffs in Israel, U.S. Reuters
 

Viewing all articles
Browse latest Browse all 2659

Trending Articles